Cargando…
New Therapies for Dedifferentiated Papillary Thyroid Cancer
The number of thyroid cancers is increasing. Standard treatment usually includes primary surgery, thyroid-stimulating hormone suppressive therapy, and ablation of the thyroid remnant with radioactive iodine (RAI). Despite the generally good prognosis of thyroid carcinoma, about 5% of patients will d...
Autores principales: | Fallahi, Poupak, Mazzi, Valeria, Vita, Roberto, Ferrari, Silvia Martina, Materazzi, Gabriele, Galleri, David, Benvenga, Salvatore, Miccoli, Paolo, Antonelli, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394525/ https://www.ncbi.nlm.nih.gov/pubmed/25789503 http://dx.doi.org/10.3390/ijms16036153 |
Ejemplares similares
-
Personalization of Targeted Therapy in Advanced Thyroid Cancer
por: Fallahi, Poupak, et al.
Publicado: (2014) -
Selective use of vandetanib in the treatment of thyroid cancer
por: Fallahi, Poupak, et al.
Publicado: (2015) -
MON-566 Early Diagnosis of Lymph Node Metastases by Serum Tg and Neck Ultrasonography, and Long Term Follow Up After Radioiodine and/or Surgical Treatment in Patients with Papillary or Follicular Thyroid Cancer.
por: Fallahi, Poupak, et al.
Publicado: (2019) -
Molecular Targeted Therapies of Aggressive Thyroid Cancer
por: Ferrari, Silvia Martina, et al.
Publicado: (2015) -
Peroxisome Proliferator-Activated Receptor-γ in Thyroid Autoimmunity
por: Ferrari, Silvia Martina, et al.
Publicado: (2015)